Tenofovir alafenamide is used in the treatment of chronic hepatitis B virus (HBV) infection. Tenofovir alafenamide acts as a prodrug that enters hepatocytes, converting to tenofovir and subsequently phosphorylated to tenofovir diphosphate, which inhibits HBV replication through viral DNA incorporation and chain termination.
🛒 How to order this item?
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Show More
Active Ingredient: Tenofovir alafenamide
Class: Anti-viral drug
Alfavir 25 is used to manage chronic hepatitis B infection in adolescents and adults aged 12 years and older. Hepatitis B is a virus that primarily infects the liver, causing long-term infection that can lead to liver damage. Symptoms of hepatitis B can include:
Before taking Alfavir 25, inform your doctor if you have:
The most common side effects of Alfavir 25 Tablet include:
- Alfavir 25 should be used with caution in pregnant women.
- It is not recommended for use in breastfeeding women.
- Before starting treatment, your doctor may require several blood tests to assess your current condition and liver function.
- During treatment, take precautions to avoid sexual contact to prevent spreading the infection to others.
- Not recommended for children under 12 years of age or those weighing less than 35 kg.
- Use with caution in elderly patients aged 65 years and above.
Avoid drinking alcohol. Consuming alcohol while using Alfavir 25 may worsen the condition.
It is unclear if Alfavir 25 mg harms unborn babies. Women who are pregnant or plan to become pregnant should inform their healthcare provider. There is a pregnancy registry for women taking antiviral medicines during pregnancy to collect health data on mothers and babies.
It is unknown whether Tenofovir alafenamide and its metabolites are excreted in human breast milk. While Tenofovir has been found in the milk of lactating animals, it is not known if Alfavir 25 mg is present in animal milk. The benefits of breastfeeding should be weighed against the mother's need for the medication and the potential effects on the breastfed infant.
Alfavir 25 can cause dizziness. If you feel dizzy when taking Alfavir 25, do not drive or use any tools or machines.
Consult your doctor before taking Alfavir 25 if you have a liver impairment or any concerns regarding this. Your doctor will weigh the benefits and any potential risks before prescribing them to you.
Consult your doctor before taking Alfavir 25 if you have kidney impairment or any concerns regarding this. Your doctor will weigh the benefits and any potential risks before prescribing them to you.
Treatment of Chronic Hepatitis B
In the event of an overdose, monitor the patient for toxicity. General supportive measures should be taken, including monitoring vital signs and clinical status. Tenofovir is effectively removed by hemodialysis.
It prevents the multiplication of viruses in human cells. This stops the virus from producing new viruses and clears up your infection.
Alfavir 25 mg is a nucleoside analog reverse transcriptase inhibitor indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults with compensated liver disease.
Tenofovir alafenamide is a phosphonamidate prodrug of tenofovir, a 2'-deoxyadenosine monophosphate analog. It is a lipophilic compound that enters primary hepatocytes through passive diffusion and hepatic uptake transporters OATP1B1 and OATP1B3. Once inside the hepatocytes, tenofovir alafenamide is converted to tenofovir via hydrolysis, primarily by carboxylesterase 1 (CES1). The intracellular tenofovir is then phosphorylated by cellular kinases into the active metabolite tenofovir diphosphate, which inhibits HBV replication by incorporating into viral DNA through HBV reverse transcriptase, resulting in DNA chain termination. Tenofovir diphosphate is a weak inhibitor of mammalian DNA polymerases, including mitochondrial DNA polymerase γ, and shows no evidence of mitochondrial toxicity in cell cultures.
Testing Before Initiation:
Recommended Dosage in Adults:
Potential Interactions:
None reported
Based on data from over 660 exposures to TAF-containing regimens during pregnancy, the prevalence of birth defects was 4.2% after first-trimester exposure and 3.0% after second/third-trimester exposure. However, methodological limitations of the reporting should be considered.
It is unclear if Tenofovir alafenamide or its metabolites are present in human breast milk or affect breastfeeding. The benefits of breastfeeding should be evaluated alongside the mother's need for the drug and any potential risks to the infant.
Disclaimer:
ePharma sole intention is to ensure that its consumers get proper
information as musch as possible. Although we do not guarantee the
accuracy and the completeness of the information that provided and
here information is for informational purposes only.
The information contained herein should NOT be used as a substitute
for the advice of a qualified physician. This may not cover
everything about particular health conditions,
lab tests, medicines, all possible side effects, drug interactions,
warnings, alerts, etc. Please consult your healthcare professional
and discuss all your queries related to any disease or medicine. We
intend to support, not replace, the doctor-patient relationship.